Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: 1363089; EXEL-2880; GSK 089; GSK 1363089; GSK 1363089G; XL 880

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Exelixis
  • Developer GlaxoSmithKline; National Cancer Institute (Canada)
  • Class Anilides; Antineoplastics; Quinolines; Small molecules
  • Mechanism of Action Proto-oncogene protein c-met inhibitors; Vascular endothelial growth factor receptor-2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Breast cancer; Gastric cancer; Head and neck cancer; Liver cancer; Non-small cell lung cancer; Renal cancer

Most Recent Events

  • 01 Mar 2015 GlaxoSmithKline completes a phase I trial for Liver cancer in Hong Kong, Taiwan, and Thailand (NCT00920192)
  • 01 Feb 2015 GlaxoSmithKline completes a phase I/II trial in Non-small cell lung cancer (Second-line therapy or greater, Late-stage disease) in Canada (NCT01068587)
  • 24 Jan 2014 GlaxoSmithKline plans a phase II trial for Non-small cell lung cancer (combination therapy, metastatic disease) in the USA (NCT02034097)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top